

Company Registration No. 4765447

**Speciality European Pharma (Europe) Limited**

**Report and Financial Statements**

**For the year ended 31 December 2013**

SATURDAY



\*A3J8YGJF\*

A26

25/10/2014

#232

COMPANIES HOUSE

# **Speciality European Pharma (Europe) Limited**

## **Report and financial statements 2013**

### **Officers and professional advisers**

#### **Director**

H.G. McMillan

P.J. Banks

#### **Secretary**

P.J. Banks

#### **Registered office**

14 Took's Court

London

EC4A 1LB

# Speciality European Pharma (Europe) Limited

## Director's report

The directors presents their report and financial statements for the Company for the year ended 31 December 2013.

### PRINCIPAL ACTIVITY

The Company was not engaged in any activity during the year.

### BUSINESS REVIEW

The results of the Company for the year under review are shown on page 3. The state of the Company's affairs at 31 December 2013 was satisfactory.

### DIRECTORS

The directors who served throughout the year, except as noted, were as follows:

P.J. Banks (appointed 26 April 2013)

H.G. McMillan

### DIVIDENDS

The directors do not recommend the payment of a dividend for the financial year currently under review.

Approved by the Board of Directors  
and signed on behalf of the Board



P J Banks  
Secretary

30 September 2014

# Speciality European Pharma (Europe) Limited

## Profit and loss account Year ended 31 December 2013

	Year Ended 31 December 2013 £	Year Ended 31 December 2012 £
Turnover	-	-
Operating income	-	-
<b>Profit (loss) on ordinary activities before taxation</b>	-	-
Tax on profit (loss) on ordinary activities	-	-
<b>Profit (loss) on ordinary activities after taxation, being retained profit (loss) for the financial period</b>	-	-
Balance brought forward	(2)	(2)
<b>Balance carried forward</b>	<u>(2)</u>	<u>(2)</u>

None of the Company's activities were acquired or discontinued during the financial year.

The Company made no recognised gains or losses in the year ended 31 December 2013 other than as shown above.

The notes on page 5 form part of these accounts

# Speciality European Pharma (Europe) Limited

## Balance sheet 31 December 2013


	Note	2013 £	2012 £
Fixed assets		-	-
Creditors: amounts falling due within one year		-	-
Total net assets		-	-
Capital and reserves			
Called up share capital	2	2	2
Profit and loss account		(2)	(2)
Total shareholders' funds		-	-

In approving these financial statements as a Director of the Company, I hereby confirm:-

- a) that for the period in question the Company was entitled to the exemption conferred by Section 480 of the Companies Act 2006 relating to dormant companies;
- b) that no notice has been deposited at the registered office of the Company pursuant to Section 476 of the Companies Act 2006 requesting that an audit be conducted for the year ended 31 December 2013; and
- c) that I acknowledge my responsibilities for:-
  - a. ensuring that the Company keeps accounting records which comply with the Companies Act 2006, and
  - b. preparing accounts which give a true and fair view of the state of affairs of the Company as at the end of the financial period and of its results for the period then ended and which otherwise comply with the provisions of the Companies Act 2006 relating to accounts, so far as applicable to the Company.

The notes on page 5 form part of these accounts.

These accounts were approved by the Board on 30 September 2014.



P.J. Banks  
Director

# Speciality European Pharma (Europe) Limited

## Notes to the financial statements Year ended 31 December 2013

### 1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the year and the preceding year.

#### Basis of accounting

The financial statements have been prepared under the historical cost convention and in accordance with applicable United Kingdom accounting standards.

#### Turnover

Turnover represents the net amount of invoices to customers less credit notes for goods returned, excluding VAT.

#### Cashflow statement

The Company has taken advantage of the exemption in Financial Reporting Standard No. 1 from producing a cash flow statement on the grounds that it is a small company.

### 2. Called up share capital

	2013 £	2012 £
<b>Authorised:</b> 1,000 (2012: 1,000) ordinary shares of £1 each	1,000	1,000
<b>Called up, allotted and fully paid</b> 2 (2012: 2) ordinary shares of £1 each	2	2

### 3. Controlling party

The ultimate holding company is Speciality European Pharma Limited, a company registered in England & Wales.